Results 41 to 50 of about 21,108 (240)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects

, 2023
Hyun Chul Kim,1,2 Sangmi Lee,1,2 Siyoung Sung,3 Eunjin Kim,3 In-Jin Jang,1 Jae-Yong Chung4 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; 2Integrated Major in ...
Lee S, Jang IJ, Kim E, Sung S, Kim HC, Chung JY   +5 more
core  

Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes

Heliyon, 2023
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) clinically reduce atherosclerosis and lower blood pressure. However, their impact on endothelial dysfunction in type 2 diabetes (T2D) remains unclear.
Shi Tai, Ying Zhou, Liyao Fu, Huiqing Ding, Yuying Zhou, Zhiyi Yin, Rukai Yang, Zhenjiang Liu, Shenghua Zhou   +8 more
doaj   +1 more source

Exploring the effect of dapagliflozin on coronary inflammation in type 2 diabetes patients based on the coronary artery perivascular fat attenuation index

Cardiovascular Diabetology
Background The pericoronary fat attenuation index (FAI) is a novel biomarker that serves as an indicator of coronary artery inflammation. Dapagliflozin has become an important component of standard treatment for type 2 diabetes because of its ...
Xuehua Liu, Tian Zhang, Rong Fu, Dan Liu, Jingyi Zhang, Qing Hu, Guangyao Song, Luping Ren   +7 more
doaj   +1 more source

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

Cardiovascular Diabetology, 2023
Background This post-hoc analysis of the DELIGHT trial assessed effects of the SGLT2 inhibitor dapagliflozin on iron metabolism and markers of inflammation.
Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink   +10 more
doaj   +1 more source

T‐Cell Remodeling in Renal Fibrosis: From Acute Injury to Chronic Kidney Disease

Advanced Science, EarlyView.
This Review presents renal fibrosis as a sequence of overlapping T‐cell programs, from chemokine‐guided recruitment and metabolic activation to maladaptive polarization, tertiary lymphoid structure formation, tissue residency, exhaustion, and senescence.
Qianhui Li, Junting Guan, Yifan Song, Hongxia Yang, Guangtao Li, Xiaodong Zhao, Jiaxin Liu, Bin Liu, Yang Tan, Honglan Zhou, Yang‐He Zhang, Yishu Wang   +11 more
wiley   +1 more source

Production, use, transfer of prodrug substances, and direct or indirect infringement of the patent: Focusing on the dapagliflozin formate case

Journal of Intellectual Property
This study explored whether the utilization of dapagliflozin formate, a dapagliflozin prodrug, constitutes direct (including literal infringement and infringement under the doctrine of equivalents) and indirect infringement, against a patent covering a ...
Kwanshik Kim
doaj   +1 more source

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

Frontiers in Pharmacology, 2022
Background: Elevated soluble urokinase plasminogen activator receptor (suPAR) is highly associated with increased risk of diabetic complications. Dapagliflozin is a drug inhibiting the sodium-glucose co-transporter 2 in the kidney to decrease blood ...
Viktor Rotbain Curovic, Morten B. Houlind, Tine W. Hansen, Jesper Eugen-Olsen, Jens Christian Laursen, Mie K. Eickhoff, Frederik Persson, Peter Rossing, Peter Rossing   +8 more
doaj   +1 more source

Not so critical appraisal of dapagliflozin [PDF]

, 2014
Sheila A Doggrell School of Biomedical Science, Faculty of Health, Queensland University of Technology, Brisbane, QLD, AustraliaA recent review by Salvo et al published in Patient Preference and Adherence concerned dapagliflozin, and was titled &ldquo ...
Doggrell SA
core  

Prognosis of patients eligible for dapagliflozin in acute heart failure

, 2020
Background: Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, was shown in the DAPA-HF study to reduce the risk of worsening heart failure or death in symptomatic patients with left ejection fraction <40%, irrespective of diabetes. The aim of
Serratrice, Jacques, Carballo, Juan Sebastian, Garin, Nicolas, Carballo, David Andrés, Stirnemann, Jérôme, Darbellay, Pauline   +5 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source